Table 1.

Trials included^a

Study	Citation	Accrual year	Median OS follow-up, y	Comparison	Sample size, No.
MOSAIC	André et al., 2004 (5)	1998-2001	9.6	C: LV5FU2	672
				E: LV5FU2 + oxaliplatin	669
C07	Kuebler et al., 2007 (6)	2000-2002	8.0	C: 5FU/LV	860
				E: FLOX	853
C89803	Saltz et al., 2007 (10)	1999-2001	7.7	C: 5FU/LV	606
				E: 5FU/LV + irinotecan	620
PETACC3	Van Cutsem et al., 2009 (11)	1999-2002	5.7	C: 5FU/FA	1139
				E: 5FU/FA + irinotecan	1120
XELOXA	Schmoll et al., 2015 (12)	2003-2004	7.0	C: 5FU/LV	909
				E: capecitabine + oxaliplatin	907
C08	Allegra et al., 2011 (13)	2004-2006	6.4	C: mFOLFOX6	994
				E: mFOLFOX6 ++ bevacizumab	985
PETACC8	Taieb et al., 2014 (8)	2005-2009	7.5	Comparison 1: KRAS WT
				C: FOLFOX4	644
				E: FOLFOX4 + cetuximab	652
				Comparison 2: KRAS MT
				C: FOLFOX4	322
				E: FOLFOX4 + cetuximab	316
				Comparison 3: KRAS Unknown
				C: FOLFOX4	312
				E: FOLFOX4 + cetuximab	312
N0147	Alberts et al., 2012 (9)	2004-2009	6.6	Comparison 1: KRAS WT
				C: mFOLFOX6	951
				E: mFOLFOX6 + cetuximab	944
				Comparison 2: KRAS MT
				C: mFOLFOX6	391
				E: mFOLFOX6 + cetuximab	344
				Comparison 3: KRAS WT
				C: FOLFIRI	71
				E: FOLFIRI + cetuximab	27
AVANT	de Gramont et al., 2012 (14)	2004-2007	6.2	Comparison 1:
				C: FOLFOX4	901
				E: FOLFOX4 + bevacizumab	948
				Comparison 2:
				C: FOLFOX4	901
				E: XELOX + bevacizumab	927

^a C = control arm; E = experimental arm; FA = folinic acid; FLOX = 5-flurouracil, leucovorin, oxaliplatin; FOLFIRI = folinic acid, 5-flurouracil, irinotecan; FOLFOX = folinic acid, 5-flurouracil, oxaliplatin; KRAS MT = KRAS mutation; KRAS WT = KRAS wild type; LV5FU2 = leucovorin and 5-flurouracil; XELOX = capecitabine plus oxaliplatin.